Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Leukemia cell lines resistant to cytosine arabinoside, cyclophosphamide or daunomycin are equally sensitive to the drug acetyldinaline as the parental cell line

Leukemia volume 14, pages 213–214 (2000)Cite this article

Acetyldinaline (ACD) (CI-994, GOë 5549, 4-acetylamine-N-(2′-aminophenyl)-benzamide) is the active and predominant metabolite of the parent compound dinaline (GOë 1734, 4-amino-N (2′-aminophenyl)-benzamide). Both compounds revealed a marked cytostatic and immuno-suppressive capacity in various animal tumor models that are highly refractory to commonly used anticancer agents.1 In addition, ACD showed a high anti-leukemia effect in the BNML rat acute myelocytic leukemia model,2 while at the same time ACD has only minor toxicity to normal pluripotent hemopoietic stem cells (HSC) as we have previously shown.3 ACD is currently being evaluated in phase 1 clinical trials.

Despite successful remission induction and consolidation treatment of acute leukemia with cytostatic agents, the majority of AML cases eventually develop a leukemia relapse. This implies that the leukemic cells have either developed drug resistance or that they already had a natural resistance and were selected out by the treatment.4

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Berger MR, Bischoff H, Fritschi E, Henne T, Herrmann M, Pool BL, Satzinger G, Schmahl D, Weiershausen U . Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2′-aminophenyl)-benzamide: a new compound preferentially active in slowly growing tumors Cancer Treat Rep 1985 69: 1415–1424

    CAS  PubMed  Google Scholar 

  2. El-Beltagi HM, Martens ACM, Dahab GM, Hagenbeek A . Efficacy of acetyldinaline for treatment of minimal residual disease (MRD)–preclinical studies in the BNML rat model for human acute myelocytic leukemia Leukemia 1993 7: 1795–1800

    CAS  PubMed  Google Scholar 

  3. El-Beltagi HM, Martens AC, Lelieveld P, Haroun EA, Hagenbeek A . Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells. Preclinical studies in a relevant rat model for human acute myelocytic leukemia Cancer Res 1993 53: 3008–3014

    CAS  PubMed  Google Scholar 

  4. Skipper HE . Some thoughts on intrinsic versus acquired drug resistance in cancers that are classified as responsive, refractory or very refractory to chemotherapy. Booklet 10 Southern Research Institute: Birmingham, AL 1986

  5. Martens ACM, Van Bekkum DW, Hagenbeek A . The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)) (review) Leukemia 1990 4: 241–257

    CAS  PubMed  Google Scholar 

  6. Hagenbeek A, Martens AC, Colly LP . In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia Semin Oncol 1987 14: (2 Suppl. 1) 202–206

    CAS  PubMed  Google Scholar 

  7. Martens AC, de Groot CJ, Hagenbeek A . Development and characterisation of a cyclophosphamide resistant variant of the BNML rat model for acute myelocytic leukaemia Eur J Cancer 1991 27: 161–166

    Article  CAS  Google Scholar 

  8. Schaider H, Haberkorn U, Stohr M, Berger MR . Dinaline inhibits amino acid transport and proliferation of colon carcinoma cells in vitro Anticancer Res 1995 15: 2501–2509

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Medical Center Utrecht, Jordan Laboratory/Hemato Oncology, Utrecht, The Netherlands

    HM El-Beltagi, ACM Martens & A Hagenbeek

Authors
  1. HM El-Beltagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. ACM Martens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Hagenbeek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Beltagi, H., Martens, A. & Hagenbeek, A. Leukemia cell lines resistant to cytosine arabinoside, cyclophosphamide or daunomycin are equally sensitive to the drug acetyldinaline as the parental cell line. Leukemia 14, 213–214 (2000). https://doi.org/10.1038/sj.leu.2401642

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401642

Search

Advanced search

Quick links